key: cord-0968932-bwin217f
authors: Zhao, Jing; Li, Hang; Kung, David; Fisher, Marc; Shen, Ying; Liu, Renyu
title: Impact of the COVID-19 Epidemic on Stroke Care and Potential Solutions
date: 2020-05-26
journal: Stroke
DOI: 10.1161/strokeaha.120.030225
sha: 775cf908302f9b5f7b1234cb1a7dfd51b6fbe227
doc_id: 968932
cord_uid: bwin217f

BACKGROUND AND PURPOSE—: When the coronavirus disease 2019 (COVID-19) outbreak became paramount, medical care for other devastating diseases was negatively impacted. In this study, we investigated the impact of the COVID-19 outbreak on stroke care across China. METHODS—: Data from the Big Data Observatory Platform for Stroke of China consisting of 280 hospitals across China demonstrated a significant drop in the number of cases of thrombolysis and thrombectomy. We designed a survey to investigate the major changes during the COVID-19 outbreak and potential causes of these changes. The survey was distributed to the leaders of stroke centers in these 280 hospitals. RESULTS—: From the data of Big Data Observatory Platform for Stroke of China, the total number of thrombolysis and thrombectomy cases dropped 26.7% (P<0.0001) and 25.3% (P<0.0001), respectively, in February 2020 as compared with February 2019. We retrieved 227 valid complete datasets from the 280 stroke centers. Nearly 50% of these hospitals were designated hospitals for COVID-19. The capacity for stroke care was reduced in the majority of the hospitals. Most of the stroke centers stopped or reduced their efforts in stroke education for the public. Hospital admissions related to stroke dropped ≈40%; thrombolysis and thrombectomy cases dropped ≈25%, which is similar to the results from the Big Data Observatory Platform for Stroke of China as compared with the same period in 2019. Many factors contributed to the reduced admissions and prehospital delays; lack of stroke knowledge and proper transportation were significant limiting factors. Patients not coming to the hospital for fear of virus infection was also a likely key factor. CONCLUSIONS—: The COVID-19 outbreak impacted stroke care significantly in China, including prehospital and in-hospital care, resulting in a significant drop in admissions, thrombolysis, and thrombectomy. Although many factors contributed, patients not coming to the hospital was probably the major limiting factor. Recommendations based on the data are provided.

July 2020

in China. In 2018, there were 200 hospitals registered in BOSC; these hospitals have registered data in 2018, 2019, and 2020 for comparison purposes. BOSC monitored a significant drop in both the thrombolysis and thrombectomy cases from January to February in 2020 as compared with the same period in 2019. We designed a survey to investigate the major changes in stroke care during the COVID-19 outbreak. A focus on February data for both 2019 and 2020 was selected for this study because the burden of COVID-19 peaked during February in China, and March data were not available at the time of investigation. Some hospitals were designated by the government as COVID-19 centers in February 2020. Confirmed or suspected COVID-19 patients identified elsewhere were generally transferred to these designated hospitals for centralized care. To speed up the investigation, we only asked specific questions on major changes, including the changes in prehospital and in-hospital care of patients with stroke (Appendix).

This is a retrospective and simple descriptive study. Data are presented as actual numbers or as percentages. χ 2 with Yates correction was used to calculate 2-tailed P using Graphpad Prism (version 8.2.1; San Diego, CA).

Among the 280 hospitals in the data registry of BOSC, the numbers of thrombolysis cases did not change significantly in January (3397) and February (3422) of 2019 but dropped significantly from 3638 cases in January 2020 to 2508 in February 2020 (31.1% decrease; P<0.0001). The numbers of thrombectomy cases did not change significantly in January (1334) and February (1298) 

There were a total of 227 valid and complete datasets from the survey of the 280 stroke centers. The retrieval rate of 81% covers 29 of 31 provinces and municipalities across China. Nearly 50% of the hospitals were designated hospitals for COVID-19, as indicated in Table 2 . The capacity and capability of stroke care was reduced and impaired in the majority of these hospitals. In 2020, hospital admissions related to stroke dropped by ≈40% as compared with the same period in 2019. Based on Table 3 ). The majority of the stroke centers have stopped or reduced their efforts in stroke education for the public. There was no difference in the pattern of changes between hospitals designated for COVID-19 and nondesignated hospitals.

As indicated in Table 3 , patients or patients' families not coming to the hospital is likely the most important factor resulting in reduced hospital admission rate and reduced thrombolysis and thrombectomy cases. Deficiencies in stroke awareness is the second critical factor, as we have discussed in the past in the absence of the pandemic. [4] [5] [6] Other contributing factors are listed in Table 4 , such as lack of adequate transportation methods, including insufficient ambulance resources. Only a small portion of hospitals closed its fast-track stroke care channels. The COVID-19 screening process was considered the major factor that caused the potentially increased door-to-needle time, although we do not have the actual data. Febrile patients affected the stroke evaluation process, and insufficient stroke medical staff could also affect door-to-needle time.

The major finding of this study was that stroke care in China was significantly affected by the outbreak of COVID-19, with a significant reduction in both thrombolysis and thrombectomy. The change in the number of treatment cases was consistent between the National Data Registry of BOSC from 280 hospitals and our survey results from 227 hospitals, with a similar drop in the number of thrombolysis and thrombectomy cases (around 25%) in February 2020 as compared with February 2019. The most prominent factor was that patients with stroke were not coming to the hospital for various reasons. The screening process for COVID-19 also interfered with stroke care significantly.

While we observed a significant drop in the absolute number of thrombolysis and thrombectomy cases, the rate of thrombolysis and thrombectomy increased slightly. The thrombolysis 

July 2020 treatment rate increased from 7.9% in February 2019 to 9.4% in February 2020, which is similar to the 8.6% rate reported in the US Get With The Guidelines Registry published in 2017. 7 The thrombectomy rate increased from 2.7% in February 2019 to 3.4% in February 2020, which is similar to the 3.3% rate reported in the United States in 2017 for all patients with ischemic stroke at all hospitals. 8 While the changes were small, they were statistically significant due to the large sample size. Thus, the drop in the absolute number of thrombolysis and thrombectomy cases is due to the drop in stroke admissions. The drop in the absolute number of therapeutic interventions likely had a profound negative impact on stroke outcome. First of all, the stroke-related disability likely increased. Based on Table 3 for the data from 227 hospitals, there were 13 144 (34 725-21 581) fewer stroke admissions. Assuming the stroke incidence is unchanged from 2019 to 2020 and assuming a conservative 8% thrombolysis rate, the drop in stroke admissions resulted in 1051 fewer patients being treated with thrombolysis. Similarly, assuming a conservative 3% thrombectomy rate, ≈394 fewer patients received thrombectomy intervention. Additionally, the patients who were not admitted to the hospital potentially lost the opportunity to have appropriate secondary prevention treatment such as carotid revascularization, anticoagulation for atrial fibrillation, antiplatelet therapies, as well as lipid lowering and blood pressure management. The loss of appropriate secondary stroke prevention would have a significant impact on recurrent stroke rate. It is important to note that here we present only a 1-month data comparison from <300 hospitals out of a large number of hospitals that have a stroke center in China.

Patients not coming to the hospital for an immediate evaluation of acute stroke is nothing new; however, this became more prominent during the outbreak of COVID-19. On top of a lack of stroke knowledge, the lack of knowledge compounded with fear of the virus made patients with stroke much less likely to seek help. The emphasis on social distancing might have inappropriately persuaded patients with acute stroke to avoid in-person medical care. Increased social isolation may also have decreased the chance of friends and family members recognizing that a patient was having a stroke. Proper education including stroke awareness and COVID-19 knowledge is needed in countries affected by COVID-19. Stroke awareness education is probably never so important as during a pandemic. Unfortunately, the majority of the hospitals stopped or reduced stroke awareness education.

Under city lockdown, the availability of transportation became severely limited. However, as long as there are sufficient ambulances and drivers, prehospital delay time should be reduced due to less traffic. Stroke priority triage plans should be established for conditions of limited emergency resources. We initially hypothesized that there would be a difference in the number of admissions between designated and undesignated hospitals; however, this assumption was not supported by the data. This could potentially be explained by patients going to the hospital that they would normally go to and not being aware which hospitals were designated as COVID-19 centers. Another possibility is the relatively robust system of stroke care networks across China.

The COVID-19 screening process could add a significant barrier to door-to-needle time and groin puncture for timely thrombolysis and thrombectomy. During the pandemic, all patients admitted to the hospital needed to have epidemiological screening and relevant examinations, which added a significant in-hospital delay for a time-sensitive disease like stroke. When laboratory resources and computed tomography (CT) scanners are occupied by a large number of patients with potential COVID-19, proper resource management needs to prioritize time-sensitive diseases such as stroke and myocardial infarction. Due to potential false negative results in the currently available coronavirus serology test, and the fact that many patients may be asymptomatic for COVID-19, the screening process should not delay timely therapy. The protocol for infectious disease should be initiated with proper personal protective equipment. It is important to note that because hospitals have potentially the highest density of patients with COVID-19, to protect the patient, the patient must wear a mask at all times in the hospital. Such a policy also protects the medical providers. The scientific evidence indicates that putting a mask on the potential infectious source offers the highest protection 9 ; this is called infectious source control. Policies to protect the healthcare team, such as proper application of personal protection equipment for the care team, and patient isolation during evaluation and treatment, added significant time to delivery of time-sensitive stroke treatment. With the rise of intravenous tissue-type plasminogen activator use and more recently acute stroke thrombectomy, much effort was devoted to optimize the timing of therapeutic delivery. The current viral pandemic has added new obstacles to the system and requires constant adaptation as our knowledge of the disease, and local resources and policies, changes daily.

Resource management is critical during a pandemic. Such resources include relevant experts, other assisting personnel, equipment, laboratory examination, and personal protective equipment, etc. As we analyzed the data, we noticed that a small portion of hospitals have closed their stroke care channels. As we proposed in our recent editorial, it might be beneficial to have designated stroke centers during the crisis to ensure adequate resources are available to offer high-quality stroke care. 1 The emergency medical service and the public should be informed that suspected stroke patients should be sent to such designated hospitals.

Based on the data, we are making the following recommendations for stroke care during the crisis of the COVID-19 pandemic:

1. Improving stroke awareness during the crisis is the key. Stroke awareness education activities should not stop or be reduced; they should be enhanced. A robust systematic educational network should be established and enhanced to educate patients on what to do during the pandemic. 2. Establishing a fast-track COVID-19 screening process for patients with potential stroke is highly desirable. One practical approach is to have a full chest CT scan together with the head and neck CT angiogram scan for all potential stroke patients. Existing evidence suggests a good correlation between chest CT scan findings and reverse transcription polymerase chain reaction testing in COVID-19. 10, 11 A positive CT scan appears before symptoms in many cases and before a positive virology test in some patients. 11, 12 The initial CT should include bilateral multilobar ground-glass opacification, mainly in the lower lobes, which is not included in the current routine practice for CT scan for patients with stroke. 

This is a simple descriptive study. We did not investigate the incidence of virus infection among patients with stroke, nor did we investigate whether virus infection affected stroke outcomes. No actual time for prehospital or in-hospital delays (door-to-needle time) was ascertained. The potential reasons for such delays are largely observational. Further study of these issues is needed. Another limitation of this study is that the data were obtained from highly selected stroke centers that have been certified by an official certification bureau. We used 3 sets of data from different numbers of hospitals, which could potentially be confusing. The mechanism of the increase in the number of thrombolysis and thrombectomy from 2018 to 2019 is unclear. It could have been caused by rapid development of stroke centers in these hospitals or by better data registration.

In conclusion, the COVID-19 outbreak affected stroke care significantly, impairing both prehospital and in-hospital care, resulting in a significant decline in thrombolysis and thrombectomy. Patients not coming to the hospital was likely a major limiting factor. Patients with stroke should be encouraged to come to the hospital and be reassured that they will have infectious disease precautions. Enhanced stroke awareness activities, proper resource management, and stroke center designation during the crisis are needed. Recommendations based on the data are provided.

Challenges and potential solutions of stroke care during the coronavirus disease 2019 (COVID-19) outbreak

Temporary emergency guidance to US stroke centers during the COVID-19 pandemic

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Significant stroke knowledge deficiencies in community physician improved with stroke 120

Stroke 112: a universal stroke awareness program to reduce language and response barriers

Stroke 1-2-0: a rapid response programme for stroke in China

Differences in acute ischemic stroke quality of care and outcomes by primary stroke center certification organization

Increase in endovascular therapy in get with the guidelines-stroke after the publication of pivotal trials

Quantifying exposure risk: surgical masks and respirators

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Chest CT for typical 2019-NCOV pneumonia: relationship to negative RT-PCR testing

We thank Andrea Ball for contributing her time for careful editing to improve the readability of this article. Drs Zhao and Liu contributed to the study concept and design, data acquisition and analysis, and manuscript preparation. Drs Li and Shen contributed to the data collection and analysis and manuscript preparation. Drs Kung and Fisher contributed to the data analysis and manuscript preparation.

We appreciate the funding support from the National Natural Science Foundation of China (81973157, principal investigator: Dr Zhao), Shanghai Natural Science Foundation (17dz2308400, principal investigator: Dr Zhao), and China Research Engagement Funding from the University of Pennsylvania (principal investigator: Dr Liu).

None.